Abstract:Acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) are hematological malignancies with high incidence rates that respond relatively well to conventional therapies. However, a major issue is the clinical emergence of patients with relapsed or refractory (r/r) NHL or ALL. In such circumstances, opportunities for complete remission significantly decline and mortality rates increase. The recent FDA approval of multiple cell-based therapies, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (Brexucabtagene autoleucel KTE-X19), and Breyanzi (Lisocabtagene Maraleucel), has provided hope for those with r/r NHL and ALL. These new cell-based immunotherapies use genetically engineered chimeric antigen receptor (CAR) T-cells, whose success can be attributed to CAR's high specificity in recognizing B-cell-specific CD19 surface markers present on various B-cell malignancies and the subsequent initiation of anti-tumor activity. The efficacy of these treatments has led to promising results in many clinical trials, but relapses and adverse reactions such as cytokine release syndrome (CRS) and neurotoxicity (NT) remain pervasive, leaving areas for improvement in current and subsequent trials. In this review, we highlight the current information on traditional treatments of NHL and ALL, the design and manufacturing of various generations of CAR T-cells, the FDA approval of Kymriah, Yescarta Tecartus, and Breyanzi, and a summary of prominent clinical trials and the notable disadvantages of treatments. We further discuss approaches to potentially enhance CAR T-cell therapy for these malignancies, such as the inclusion of a suicide gene and use of FDA-approved drugs.

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation

CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies

Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Current state of CAR-T therapy for T-cell malignancies

Chimeric antigen receptor T-cell therapies for lymphoma

Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes

Target Selection of CAR T Cell Therapy in Accordance with the TME for Solid Tumors.

Current Progress in Chimeric Antigen Receptor T‐cell Therapy for Malignant Tumors

CD19 Chimeric Antigen Receptor T Cell Therapy for the Treatment of B Cell Lineage Acute Lymphoblastic Leukemia.

Advances of CD19-directed Chimeric Antigen Receptor-Modified T Cells in Refractory/relapsed Acute Lymphoblastic Leukemia

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Target selection for CAR-T therapy

CAR T‐cell therapy: Full speed ahead

Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia

Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Novel Immunotherapy Targets for Relapsed/Refractory B-ALL: A Literature Review

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas